(Circulation. 1996;93:810-816.)
© 1996 American Heart Association, Inc.
Articles |
From the Second Department of Internal Medicine, Tokyo (Japan) Medical and Dental University.
Correspondence to Hiroshi Ito, MD, Second Department of Internal Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113 Japan.
Background Heparan sulfate, one of the primary components of extracellular matrix, is a potent antigrowth factor in certain types of cells. To elucidate a possible role of endogenous heparin-like molecules in regulating cardiomyocyte hypertrophy, we investigated the effects of heparin and heparan sulfate on angiotensin (Ang) IIinduced hypertrophy in cultured neonatal rat cardiomyocytes.
Methods and Results Competitive [3H]heparin
binding assay showed that cardiomyocytes had specific
binding sites for heparin. In situ [3H]heparin binding
assay demonstrated that heparin, which rapidly bound to the
cardiomyocyte surface, was subsequently accumulated around
the nuclei, suggesting that heparin might work in the nucleus.
Cotreatment with heparin (20 µg/mL) completely inhibited increased
cell surface area by Ang II (10-6 mol/L).
Increased [3H]leucine incorporation by Ang II was reduced
by heparin dose-dependently. The inhibitory effect of
heparin on Ang IIinduced cardiomyocyte
hypertrophy also was confirmed by Northern blot
analysis: heparin dose-dependently inhibited skeletal
-actin and atrial natriuretic peptide gene
expression, genetic markers for cardiomyocyte
hypertrophy. Heparan sulfate showed similar
inhibitory effects on cell surface area,
[3H]leucine incorporation, and skeletal
-actin gene
expression. Treatment with heparinase I or III, which specifically
digests the disaccharide chains of endogenous
heparin-like molecules, upregulated protein synthesis and skeletal
-actin and atrial natriuretic peptide gene
expression in cardiomyocytes.
Conclusions Our findings in this study strongly suggest that heparin and heparan sulfate are potent inhibitors of cardiomyocyte hypertrophy and that endogenous heparin-like substances negatively regulate cardiomyocyte hypertrophy.
Key Words: angiotensin heparin hypertrophy
This article has been cited by other articles:
![]() |
B. Ramkhelawon, J. Vilar, D. Rivas, B. Mees, R. de Crom, A. Tedgui, and S. Lehoux Shear Stress Regulates Angiotensin Type 1 Receptor Expression in Endothelial Cells Circ. Res., October 23, 2009; 105(9): 869 - 875. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Maekawa, J.-i. Abe, T. Shishido, S. Itoh, B. Ding, V. K. Sharma, S.-S. Sheu, B. C. Blaxall, and B. C. Berk Inhibiting p90 Ribosomal S6 Kinase Prevents Na+-H+ Exchanger-Mediated Cardiac Ischemia-Reperfusion Injury Circulation, May 30, 2006; 113(21): 2516 - 2523. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. H. Thourani, S. S. Brar, T. P. Kennedy, L. R. Thornton, J. A. Watts, R. S. Ronson, Z.-Q. Zhao, A. L. Sturrock, J. R. Hoidal, and J. Vinten-Johansen Nonanticoagulant heparin inhibits NF-kappa B activation and attenuates myocardial reperfusion injury Am J Physiol Heart Circ Physiol, June 1, 2000; 278(6): H2084 - H2093. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-L. Lee, W.-W. Wang, P. M. Joseph, C. A. Hales, and B. L. Fanburg Inhibitory Effect of Heparin on Serotonin-induced Hyperplasia and Hypertrophy of Smooth Muscle Cells Am. J. Respir. Cell Mol. Biol., July 1, 1997; 17(1): 78 - 83. [Abstract] [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1996 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |